Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.
News & Analysis: Sarepta Therapeutics
SRPT earnings call for the period ending March 31, 2019.
Want to invest like the great value investor? These stocks might appeal to you.
It's hard not to get excited about this company's experimental gene therapy for Duchenne muscular dystrophy.
These stocks took larger hits than the overall market. Find out why.
SRPT earnings call for the period ending December 31, 2018.
Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.
Here's why a competitor's pain was Sarepta's gain recently.
Clinical trial readouts on the way will move these stocks before 2019's finished.
Here's what you need to know about the FDA's latest plans to meet the biotech industry halfway.